Full Text Journal Articles by
Author Neal D Shore

Advertisement

Find full text journal articles






Reply by Authors.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

J Urol (The Journal of urology)
[2021, :101097JU000000000000177803]

Cited: 0 times

View full text PDF listing >>



Combined advanced prostate cancer treatments: are they additive?

Abhishek Srivastava, Neal D Shore,

Nat Rev Urol (Nature reviews. Urology)
[2021, 18(6):325-326]

Cited: 0 times

View full text PDF listing >>



Advertisement

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

<h4>Purpose</h4>We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia.<h4>Materials and methods</h4>A total of 197 subjects <u>></u>50 years of age with International Prostate Symptom Score ≥13, maximum flow ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001778]

Cited: 0 times

View full text PDF listing >>



Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.

Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L Amorosi, Neal D Shore,

<b>Background:</b> Benign prostatic hyperplasia (BPH) is one of the most prevalent and costly chronic conditions among middle-aged and elderly men. Prostatic urethral lift (PUL) and convective water vapor thermal therapy (WVTT) are emerging minimally invasive surgical treatments as an alternative to traditional treatment options for men with moderate-to-severe BPH. This ... Read more >>

J Health Econ Outcomes Res (Journal of health economics and outcomes research)
[2021, 8(1):42-50]

Cited: 0 times

View full text PDF listing >>



Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors.

Alicia K Morgans, Joseph Renzulli, Kara Olivier, Neal D Shore,

Prostate cancer (PC) is primarily a disease of older men. As the risk of neurocognitive decline increases as people age, cognitive dysfunction is a potential complication in men with PC, imposing detrimental effects on functional independence and quality of life. Importantly, risk of cognitive decline may increase with exposure to ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).

Fred Saad, Kim N Chi, Neal D Shore, Julie N Graff, Edwin M Posadas, Jean-Baptiste Lattouf, Byron M Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N V S Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh, Arash Rezazadeh Kalebasty,

<h4>Purpose</h4>To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC).<h4>Methods</h4>BEDIVERE was a multicenter, open-label, phase 1b study of niraparib 200 or 300 mg/day with apalutamide 240 mg or AAP (abiraterone acetate ... Read more >>

Cancer Chemother Pharmacol (Cancer chemotherapy and pharmacology)
[2021, 88(1):25-37]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P Haas, Arnulf Stenzl,

J Urol (The Journal of urology)
[2021, 205(5):1371]

Cited: 0 times

View full text PDF listing >>



Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis.

Laurence Klotz, Giovanni Lughezzani, Davide Maffei, Andrea Sánchez, José Gregorio Pereira, Frédéric Staerman, Hannes Cash, Ferdinand Luger, Laurent Lopez, Rafael Sanchez-Salas, Rob Abouassaly, Neal D Shore, Gregg Eure, Marco Paciotti, Ander Astobieta, Laura Wiemer, Sebastian Hofbauer, Robin Heckmann, Andreas Gusenleitner, Jasmin Kaar, Clemens Mayr, Wolfgang Loidl, Jean Rouffilange, Richard Gaston, Xavier Cathelineau, Eric Klein,

<h4>Introduction</h4>High-resolution micro-ultrasound has the capability of imaging prostate cancer based on detecting alterations in ductal anatomy, analogous to multiparametric magnetic resonance imaging (mpMRI). This technology has the potential advantages of relatively low cost, simplicity, and accessibility compared to mpMRI. This multicenter, prospective registry aims to compare the sensitivity, specificity, negative ... Read more >>

Can Urol Assoc J (Canadian Urological Association journal = Journal de l'Association des urologues du Canada)
[2021, 15(1):E11-E16]

Cited: 1 time

View full text PDF listing >>



Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.

Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P Haas, Arnulf Stenzl,

<h4>Purpose</h4>Enzalutamide plus androgen deprivation therapy has previously been shown to improve clinical outcomes in men with metastatic hormone-sensitive prostate cancer (ARCHES; NCT02677896). Here, we assessed if and how the pattern of metastatic spread impacts efficacy of enzalutamide plus androgen deprivation therapy in men enrolled in ARCHES.<h4>Materials and methods</h4>Men with metastatic ... Read more >>

J Urol (The Journal of urology)
[2021, 205(5):1361-1371]

Cited: 0 times

View full text PDF listing >>



Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.

Fred Saad, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Neal D Shore, Maha Hussain,

<h4>Background</h4>There is no universally accepted definition for prostate-specific antigen (PSA) progression. However, changes in PSA in patients with castration-resistant prostate cancer (CRPC) are used to inform treatment decisions.<h4>Objective</h4>To determine whether the Prostate Cancer Working Group 2 (PCWG2) definition of PSA progression is adequate to predict radiographic or clinical progression in ... Read more >>

Eur Urol (European urology)
[2020, 78(6):847-853]

Cited: 0 times

View full text PDF listing >>



Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.

Neal D Shore, Charles G Drake, Daniel W Lin, Charles J Ryan, Kelly L Stratton, Curtis Dunshee, Lawrence I Karsh, Sanjeev Kaul, Ken Kernen, Christopher Pieczonka, Paul Sieber, Christopher Stewart, Michael Williams, Raoul S Concepcion,

<h4>Background</h4>Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations that provide a substantial and comprehensive framework, there are numerous clinical scenarios that are not always addressed, especially as new ... Read more >>

Prostate (The Prostate)
[2020, 80(14):1159-1176]

Cited: 0 times

View full text PDF listing >>



Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.

Neal D Shore, Alicia K Morgans, Charles J Ryan,

This review discusses impact of advancements in biologic understanding of prostate cancer (PCa) on definition and diagnosis of castration-resistant PCa (CRPC), predictive factors for progression to CRPC and treatment strategies. More sensitive assays confirm that bilateral orchiectomy reduces serum testosterone (T) closer to < 20 ng/dL than < 50 ng/dL, and evidence suggests ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.

Neal D Shore, David Dearnaley, Bertrand Tombal,

Eur Urol (European urology)
[2020, 78(5):e196-e197]

Cited: 0 times

View full text PDF listing >>



Development and evaluation of the MiCheck test for aggressive prostate cancer.

Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, James L Bailen, Daniel R Saltzstein, Raoul S Concepcion, Jennifer L Beebe-Dimmer, Julie J Ruterbusch, Rachel A Levin, Sandra Wissmueller, Thao Ho Le, David Gillatt, Daniel W Chan, Douglas H Campbell, Bradley J Walsh,

<h4>Background</h4>A clinical need exists for a biomarker test to accurately delineate aggressive prostate cancer (AgCaP), and thus better assist clinicians and patients decision-making on whether to proceed to prostate biopsy.<h4>Objectives</h4>To develop a blood test for AgCaP and compare to PSA, %free PSA, proPSA, and prostate health index (PHI) tests.<h4>Design, settings ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(8):683.e11-683.e18]

Cited: 1 time

View full text PDF listing >>



Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

Cora N Sternberg, Karim Fizazi, Fred Saad, Neal D Shore, Ugo De Giorgi, David F Penson, Ubirajara Ferreira, Eleni Efstathiou, Katarzyna Madziarska, Michael P Kolinsky, Daniel I G Cubero, Bettina Noerby, Fabian Zohren, Xun Lin, Katharina Modelska, Jennifer Sugg, Joyce Steinberg, Maha Hussain, ,

<h4>Background</h4>Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.<h4>Methods</h4>In this double-blind, phase 3 trial, men with nonmetastatic, ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(23):2197-2206]

Cited: 23 times

View full text PDF listing >>



The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

David P Dearnaley, Daniel R Saltzstein, John E Sylvester, Lawrence Karsh, Bryan A Mehlhaff, Christopher Pieczonka, James L Bailen, Hongliang Shi, Zhan Ye, Hélène M Faessel, Huamao Lin, Yanyan Zhu, Fred Saad, David B MacLean, Neal D Shore,

<h4>Background</h4>External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist.<h4>Objective</h4>To evaluate ... Read more >>

Eur Urol (European urology)
[2020, 78(2):184-192]

Cited: 3 times

View full text PDF listing >>



Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Neal D Shore, Fred Saad, Michael S Cookson, Daniel J George, Daniel R Saltzstein, Ronald Tutrone, Hideyuki Akaza, Alberto Bossi, David F van Veenhuyzen, Bryan Selby, Xiaolin Fan, Vicky Kang, Jackie Walling, Bertrand Tombal, ,

<h4>Background</h4>Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.<h4>Methods</h4>In this phase ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(23):2187-2196]

Cited: 19 times

View full text PDF listing >>



A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.

Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, James L Bailen, Daniel R Saltzstein, Raoul S Concepcion, Jennifer L Beebe-Dimmer, Julie J Ruterbusch, Thao Ho Le, Rachel A Levin, Sandra Wissmueller, Philip Prah, Robert Borotkanics, Thomas A Paivanas, Arletta van Breda, Douglas H Campbell, Bradley J Walsh,

<h4>Background</h4>Increasing numbers of patients are presenting with aggressive prostate cancer (CaP); therefore, there exists a need to optimally identify these patients pre-biopsy.<h4>Objectives</h4>To compare the accuracy of total prostate specific antigen (PSA), %free PSA, and prostate health index (PHI) to differentiate between patients without CaP, with non-aggressive (Gleason 3 + 3, non-AgCaP) and ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(8):683.e1-683.e10]

Cited: 0 times

View full text PDF listing >>



Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Oliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, David G McLeod, Matthew R Cooperberg, David F Penson, Philip W Kantoff, Nicholas J Vogelzang, Arif Hussain, Christopher M Pieczonka, Neal D Shore, David I Quinn, Eric J Small, Elisabeth I Heath, Ronald F Tutrone, Paul F Schellhammer, Matthew Harmon, Nancy N Chang, Nadeem A Sheikh, Bruce Brown, Stephen J Freedland, Celestia S Higano,

<h4>Purpose</h4>African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T. We explored this in PROCEED (NCT01306890), an FDA-requested registry in over 1900 patients with metastatic castration-resistant prostate ... Read more >>

Prostate Cancer Prostatic Dis (Prostate cancer and prostatic diseases)
[2020, 23(3):517-526]

Cited: 8 times

View full text PDF listing >>



Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.

Neal D Shore, Paul F Schellhammer, Ronald F Tutrone, Neil F Mariados, Stacey S Harrelson,

<h4>Background</h4>Numerous globally approved castration-resistant prostate cancer (CRPC) therapies are available. Enzalutamide and radium 223 (Ra 223) are approved for survival prolongation and ability to delay radiographic progression. Both have markedly different mechanisms of action as well as safety and tolerability profiles. We prospectively investigated their combined safety and tolerability.<h4>Patients and ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2020, 18(5):416-422]

Cited: 0 times

View full text PDF listing >>



Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Celestia S Higano, Andrew J Armstrong, Oliver Sartor, Nicholas J Vogelzang, Philip W Kantoff, David G McLeod, Christopher M Pieczonka, David F Penson, Neal D Shore, Jeffrey Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T Nordquist, David I Quinn, Vahan Kassabian, Mark C Scholz, Matt Harmon, Robert C Tyler, Nancy N Chang, Hong Tang, Matthew R Cooperberg,

Cancer (Cancer)
[2020, 126(12):2935-2937]

Cited: 0 times

View full text PDF listing >>



CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.

Neal D Shore, Matthew P Morrow, Trevor McMullan, Kimberly A Kraynyak, Albert Sylvester, Khamal Bhatt, Jocelyn Cheung, Jean D Boyer, Li Liu, Brian Sacchetta, Samantha Rosencranz, Elizabeth I Heath, Luke Nordquist, Heather H Cheng, Scott T Tagawa, Leonard J Appleman, Ronald Tutrone, Jorge A Garcia, Young E Whang, W Kevin Kelly, David B Weiner, Mark L Bagarazzi, Jeffrey M Skolnik,

The management of men with prostate cancer (PCa) with biochemical recurrence following local definitive therapy remains controversial. Early use of androgen deprivation therapy (ADT) leads to significant side effects. Developing an alternative, clinically effective, and well-tolerated therapy remains an unmet clinical need. INO-5150 is a synthetic DNA therapy that includes ... Read more >>

Mol Ther (Molecular therapy : the journal of the American Society of Gene Therapy)
[2020, 28(5):1238-1250]

Cited: 2 times

View full text PDF listing >>



Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.

Neal D Shore, Emmanuel S Antonarakis, Michael S Cookson, E David Crawford, Alicia K Morgans, David M Albala, Jason Hafron, Richard G Harris, Daniel Saltzstein, Gordon A Brown, Jonathan Henderson, Benjamin Lowentritt, Jeffrey M Spier, Raoul Concepcion,

BACKGROUND:For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well-described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The ... Read more >>

Prostate (The Prostate)
[2020, 80(6):527-544]

Cited: 6 times

View full text PDF listing >>



Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer.

Brian Schulte, Alicia K Morgans, Neal D Shore, Carmel Pezaro,

Since 1944, when Huggins and Hodges demonstrated the effectiveness of bilateral orchiectomy for metastatic prostate cancer (PCa), androgen deprivation therapy (ADT) has been the first-line treatment for men with advanced PCa. The proportion of PCa cases that are metastatic at diagnosis ranges globally, from 5%-20% in countries with widespread screening ... Read more >>

Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting)
[2020, 40:1-10]

Cited: 1 time

View full text PDF listing >>



Management of Low-grade Upper Tract Urothelial Carcinoma: An Unmet Need.

Jay Raman, Neal D Shore,

Upper tract urothelial cancers (UTUC) are frequently managed by radical nephroureterectomy (RNU), a major operative procedure that may entail short-term morbidity and long-term decline in renal function. Kidney-sparing procedures offer a less invasive alternative to RNU for low-risk, low-grade UTUC (LG-UTUC). They are associated with similar disease-specific survival rates and ... Read more >>

Rev Urol (Reviews in urology)
[2020, 22(1):1-8]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.096 s